Ensysce Biosciences shares surge 13.22% premarket after initiating enrollment in pivotal Phase 3 trial of PF614, its next-generation opioid with overdose protection.

Ensysce Biosciences surged 13.22% in premarket trading following a Diamond Equity Research update on its stock and ongoing progress in pivotal trials. The research firm’s recent positive note, combined with the company’s initiation of enrollment in a Phase 3 trial for PF614—a next-generation opioid with built-in overdose protection—underscored advancing clinical milestones and regulatory optimism. Additional catalysts included FDA feedback on manufacturing, expanded patent protection, and secured financing, all reinforcing the stock’s bullish trajectory. The premarket rally reflects investor confidence in the company’s pipeline advancements and commercialization potential.